(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 43.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.51%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.97%.
Voyager Therapeutics's revenue in 2025 is $30,907,000.On average, 5 Wall Street analysts forecast VYGR's revenue for 2025 to be $1,795,192,437, with the lowest VYGR revenue forecast at $1,202,009,026, and the highest VYGR revenue forecast at $2,503,307,215. On average, 5 Wall Street analysts forecast VYGR's revenue for 2026 to be $4,806,482,978, with the lowest VYGR revenue forecast at $443,750,448, and the highest VYGR revenue forecast at $8,095,672,236.
In 2027, VYGR is forecast to generate $4,457,251,375 in revenue, with the lowest revenue forecast at $525,289,593 and the highest revenue forecast at $6,812,124,065.